

131-Year History

Since its founding in 1890, Santen has contributed to patients and their loved ones. The spirit of our CORE PRINCIPLE, reflected in our company name, has more than 130 years of heritage. We have turned the challenges we have overcome into our strengths, and this continues to pave the way for our next growth trajectory.

Establishment— Laying the Foundation (1890-1989)

1890

Santen kicks off by taking the challenge of contributing to people's health

Santen's origins date back to 1890, when Kenkichi Taguchi opened Taguchi Santendo. *Heburin-gan*, a cold medication, was its main product at the time. In the late 19th century, many people in Japan suffered from eye disorders, and demand for eye drops was high. The company launched *Daigaku Eye Drops* in 1899 and the product's popularity spread nationwide. From that point, Santen began taking on the challenge of contributing to eye health.



1950s

Pursuing a strategy centered on eye drops, and expanding into prescription pharmaceuticals

Due to difficulties encountered from aerial bombings during World War II, Santen shifted its business strategy focusing on eye drops. In 1958, Santen entered the prescription pharmaceutical business and in 1962 launched *Mydrin-P*, which promotes mydriasis, or dilation of the pupil. This groundbreaking eye drop used in ophthalmic surgery and diagnosis contributed significantly to the development of ophthalmology in Japan. Thereafter, product launches included an innovative antibiotic ophthalmic and a glaucoma treatment, laying the foundation to support ophthalmic treatment in Japan.



Growth (1990-2009)

1990s

Strengthening the global production system toward internationalization and entering the European market

Upon its centennial in 1990, Santen embarked on a new growth stage with the announcement of a long-term vision to contribute to society with the best products and services focusing on the eye and health. In addition to business growth in Japan on the back of an expanding product lineup, and the completion of the Shiga Plant, Santen entered the European market and emphasized aggressive business development to contribute to patients around the world.



2000s

Expanding solutions and building a business foundation in Asia

Santen focused on meeting the needs of more people by providing a wide range of treatment options including intraocular lenses and supplements in addition to ophthalmic solutions for eye diseases. At the same time, the Company worked to build a business foundation in Asia, which included building a direct sales network in China as well as completing the Suzhou Plant, and establishing Group company in South Korea.



Transformation (2010-)

2010s

Rapidly accelerating globalization to contribute to eye health worldwide

Aiming to become a specialized pharmaceutical company with a global presence as its long-term vision up to 2020, Santen rapidly accelerated its globalization, centered on China, Asia and EMEA. In 2015, Santen sold its anti-rheumatic pharmaceuticals business to AYUMI Pharmaceutical Corporation to specialize in ophthalmology and concentrate its management resources in the field.



2020s
















Aspiring to Become A Social Innovator to deliver happiness through vision

Aiming to resolve eye-related social issues, the Company announced Santen 2030, a long-term vision toward 2030 and beyond. To realize "The Happiest Life for every individual through the Best Vision Experience," Santen continues to take on challenges worldwide to provide products and services with true value by bringing together knowhow and expertise through partnerships with external organizations, M&A and other approaches.




131-Year History


A Brief History of Santen's Product Innovation (Major products based on year of launch)

								
1890 <i>Heburin-gan</i> (cold medication)	1962 <i>Mydrin-P</i> (mydriatic)	1987 <i>Tarivid</i> (anti-infective ophthalmic)	1992 <i>Kary Uni</i> (treatment for early-stage senile cataracts)	2000 <i>Cravit</i> (anti-infective ophthalmic)	2008 <i>Tapros</i> (treatment for glaucoma and ocular hypertension)	2010 <i>Diquas</i> (treatment for dry eye syndrome)	2018 <i>Eybelis</i> (treatment for glaucoma and ocular hypertension)	2019 <i>LENTIS Comfort</i> (intraocular lens)
								
1899 <i>Daigaku Eye Drops</i>	1962 <i>Super Sante</i>	1991 <i>Sante FX</i>	1995 <i>Hyalein</i> (treatment for corneal disorders)	2001 <i>Livostin</i> (anti-allergy ophthalmic)	2010 <i>Cosopt</i> (treatment for glaucoma and ocular hypertension)	2015 <i>Ikervis</i> (treatment for severe keratitis in adult patients with dry eye disease)	2019 <i>Alesion LX</i> (anti-allergy ophthalmic)	

▶ Group Companies Country/Region and year of establishment indicated in parentheses



▶ Revenue



¹ Established as Novagali Pharma S.A. ² Established as Santen Switzerland SA ³ Established as TAHMIN SANTEN CO., LTD.